Sun-Ranbaxy Merger Could Take Several Months Getting India Approval
This article was originally published in PharmAsia News
The $4 billion Sun Pharmaceutical Industries acquisition of Ranbaxy Laboratories from Daiichi Sankyo appears likely to take much longer than the average 30 days for approval in India because of the deal's complexity.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.